Cost savings opportunity PSG already demonstrates a strong track record of delivering substantial savings (over $7 billion across more than 20 million lives) for health systems, plans, and large employers. This positions PSG to pursue expanded cost-management engagements with existing clients and cross-sell to similar healthcare organizations seeking proven ROI.

Specialty drug focus PSG highlights expertise in specialty drug benefits and has published trends reports and participate in specialty pharmacy summits. This suggests opportunities to offer expanded specialty drug benefit design, payer strategies, and utilization management services to payers and large employers navigating rising specialty costs.

Data and analytics edge With a technology-forward approach and a suite of analytics-powered services, PSG can leverage its Artemetrx-based insights and proprietary tools to sell advanced forecasting, cost-optimization analytics, and data-enabled decision support to health plans, systems, and employers seeking evidence-based pharmacy management.

Expansion and leadership Recent leadership appointments and the company’s growth trajectory, along with acquisitions in the broader Omnicell ecosystem, indicate scalability and potential for integrated solutions (pharmacy management, 340B linkage, and tech-enabled cost controls) to existing healthcare clients and new segments like accountable care organizations.

Industry credibility PSG maintains a high retention rate and a broad client base, coupled with ongoing publication of reports and participation in industry events. This credibility can be leveraged to upsell advisory services, benchmarking programs, and consulting engagements focused on pharmacy optimization and contract negotiation support.